What is the role of immunohistochemistry in differentiating hepatocellular carcinoma from intra‑hepatic cholangiocarcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Role of Immunohistochemistry in Differentiating HCC from IHCC

Immunohistochemistry is essential for distinguishing hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (IHCC), with morphological analysis always supported by specific IHC marker panels that demonstrate hepatocellular versus cholangiocytic differentiation. 1

Recommended IHC Panel Approach

For Hepatocellular Differentiation (HCC)

The most recent EASL guidelines (2025) recommend the following markers for HCC diagnosis 1:

First-line hepatocellular markers:

  • CD10 (canalicular pattern)
  • pCEA (polyclonal CEA, canalicular pattern)
  • BSEP

These three markers demonstrate higher specificity and sensitivity compared to traditional markers like HepPar-1 and glypican-3 1.

Second-line hepatocellular markers:

  • HepPar-1
  • Arginase-1
  • Glypican-3

For Cholangiocytic Differentiation (IHCC)

According to EASL-ILCA guidelines (2023), IHCC is characterized by 2:

Cholangiocytic markers:

  • Cytokeratin 7 (positive)
  • Cytokeratin 19 (positive)
  • Cytokeratin 20 (negative)

This K7(+)/K19(+)/K20(-) pattern is characteristic of IHCC.

Critical Clinical Context: Small Duct IHCC vs HCC

A major diagnostic pitfall occurs with small duct-type IHCC, which frequently arises in patients with chronic liver disease and can mimic HCC both radiologically and clinically 2. This subtype requires particular attention because:

  • Imaging alone results in false-positive HCC diagnosis in 11.4% to 63% of IHCC cases 2
  • Small duct IHCC must be differentiated from HCC and combined HCC-CCA (cHCC-CCA)
  • Hepatocytic markers (HepPar-1, Arginase-1, ABCB11) are specific for HCC or the hepatocytic component in combined tumors 2

Practical Algorithm for IHC Interpretation

Step 1: Apply hepatocellular markers

  • If CD10, pCEA, or BSEP show canalicular pattern → strongly favors HCC
  • If Arginase-1 positive → supports HCC

Step 2: Apply cholangiocytic markers

  • If K7(+)/K19(+) → favors IHCC
  • If K7(-)/K19(-) → favors HCC

Step 3: Consider combined tumors

  • If both hepatocytic AND cholangiocytic markers are positive → suggests cHCC-CCA
  • Recognition of even just the hepatocytic component is key for identifying combined tumors 2

Important Caveats and Pitfalls

Scirrhous HCC Variant

Research demonstrates that scirrhous HCC can be particularly misleading 3:

  • Only 26% are HepPar-1 positive (vs. 74% in classical HCC)
  • 80% express adenocarcinoma-related markers (EpCAM, CK19, CK7)
  • Glypican-3 and Arginase combined yield 100% sensitivity for scirrhous HCC
  • This variant can easily be misdiagnosed as adenocarcinoma

Single Marker Limitations

Never rely on single markers alone 1. The traditional three-marker panel (glypican-3, glutamine synthetase, HSP70) shows 100% specificity but only 72% sensitivity when all three are positive 1.

Poorly Differentiated Tumors

In poorly differentiated tumors or limited biopsy samples, morphology-based interpretation may be insufficient 2. Additional markers for IHCC subtyping include:

  • Large duct type: S100p, mucicarmine
  • Small duct type: CD56, N-cadherin

Tissue Management Strategy

Always obtain non-tumoral liver parenchyma simultaneously with tumor biopsy 1. This allows:

  • Comparative histological analysis between tumor and background liver
  • Assessment of fibrosis stage and activity grade
  • Differentiation of early HCC from high-grade dysplastic nodules
  • Evaluation of co-morbid factors (particularly important in MASLD)

Performance Characteristics

The evidence quality for IHC in this differential diagnosis is moderate, with most studies being retrospective and single-center 2. However, the clinical utility is well-established, particularly given that imaging-based diagnosis alone carries substantial false-positive rates for HCC when the actual diagnosis is IHCC.

References

3
Research

Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2013

Related Questions

Can topical minoxidil cause abnormal uterine bleeding or alter the menstrual cycle?
Can I safely pause hormone replacement therapy (HRT) for three weeks and then resume it without increased risk, given that I am in my eighties and have been on HRT continuously since age 48?
Can I abruptly discontinue fluoxetine 60 mg daily and trazodone 150 mg at bedtime in this patient?
What is the normal fasting blood glucose range after an overnight fast in a healthy adult, and how are abnormal values interpreted for diabetes diagnosis?
Should an 84-year-old woman who began combined estrogen‑progestin hormone replacement therapy at age 48 continue the therapy?
In a patient whose peripheral capillary oxygen saturation (SpO₂) is fluctuating between 78% and 86% on room air without supplemental oxygen or bilevel positive airway pressure (BiPAP), what immediate interventions are indicated to improve oxygenation, and should sacubitril/valsartan (Entresto) be started now?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.